Pathological IL-1β has been indicated to inhibit glutamate reuptake and lead to N-methyl-D-aspartate (NMDA)-mediated excitotoxicity by reducing expression of the presynaptic glutamate transporter, resulting in neuronal damage and structural abnormalities in depression (45). Here, IL1B is linked to depressive symptom measurement.